Collegium Pharmaceutical Inc. (COLL)
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Mike Heffernan - Interim President and Chief Executive Officer, Founder & Chairman Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago.
Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Collegium Pharmaceutical (COLL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Amalgamated Bank Has $427,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Amalgamated Bank decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,870 shares of the specialty pharmaceutical company’s stock after selling 2,101 shares during the quarter. Amalgamated Bank’s holdings in Collegium Pharmaceutical were worth $427,000 as of its most recent SEC filing. Other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. grew its holdings in Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after acquiring an additional 272,565 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Collegium Pharmaceutical by 1,475.5% in the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after acquiring an additional 188,347 shares in the last quarter. Qube Research & Technologies Ltd increased its position in Collegium Pharmaceutical by 713.3% during the third quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after acquiring an additional 111,394 shares during the period. Finally, Federated Hermes Inc. raised its stake in Collegium Pharmaceutical by 76.0% in the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock worth $6,549,000 after purchasing an additional 91,911 shares in the last quarter. Collegium Pharmaceutical Trading Down 3.6 % Shares of COLL stock opened at $32.47 on Monday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The stock’s fifty day moving average price is $37.13 and its two-hundred day moving average price is $32.83. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The company has a market cap of $1.06 billion, a PE ratio of 13.53 and a beta of 1.06. Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.25. The business had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year. Analyst Upgrades and Downgrades A number of research analysts have issued reports on the stock. Piper Sandler lowered shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price on the stock. in a research report on Friday, May 10th. Truist Financial raised their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, February 26th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Finally, Needham & Company LLC lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Hold” and a consensus target price of $39.00. View Our Latest Analysis on COLL Insider Activity at Collegium Pharmaceutical In related news, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the transaction, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.98% of the stock is currently owned by insiders. Collegium Pharmaceutical Profile (Free Report) Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
